Glucagon Receptors (Glucagon Receptor)

Cell surface receptors that bind glucagon with high affinity and trigger intracellular changes which influence the behavior of cells. Activation of glucagon receptors causes a variety of effects; the best understood is the initiation of a complex enzymatic cascade in the liver which ultimately increases the availability of glucose to body organs.

Also Known As:

Networked: 127 relevant articles (5 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yu, Run: 8 articles (03/2014 - 11/2009)
2.	Drucker, Daniel J: 7 articles (06/2015 - 10/2005)
3.	Pocai, Alessandro: 6 articles (06/2014 - 10/2009)
4.	Charron, Maureen J: 5 articles (02/2015 - 11/2011)
5.	Dhall, Deepti: 4 articles (01/2014 - 11/2009)
6.	Carrington, Paul E: 4 articles (08/2012 - 10/2009)
7.	Marsh, Donald J: 4 articles (08/2012 - 10/2009)
8.	Andersen, Birgitte: 3 articles (12/2015 - 09/2008)
9.	Ali, Safina: 3 articles (02/2015 - 03/2009)
10.	Gelfanov, Vasily: 3 articles (01/2015 - 10/2009)

Related Diseases

1.	Hyperplasia 12/01/2009 - "Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia." 11/01/2015 - "To investigate the molecular mechanism of the α-cell hyperplasia and to identify the responsible factor, we created a zebrafish model in which glucagon receptor (gcgr) signaling has been interrupted. " 11/01/2015 - "Glucagon receptor inactivation leads to α-cell hyperplasia in zebrafish." 03/01/2014 - "Pancreatic α-cell hyperplasia (ACH) was once an esoteric pathological entity, but it has become an important differential diagnosis of hyperglucagonemia after inactivating glucagon receptor (GCGR) genomic mutations were found in patients with ACH. " 01/01/2014 - "Exocrine pancreas hyperplasia without dysplasia in glucagon receptor knockout mice."
2.	Type 2 Diabetes Mellitus (MODY) 02/01/2014 - "Identification of orally active, small molecule antagonists of the glucagon receptor represents a novel treatment paradigm for the management of type 2 diabetes mellitus. " 05/01/2015 - "Application to a concise synthesis of LY2409021, a glucagon receptor antagonist that is used in clinical trials for type 2 diabetes mellitus, is reported as well. " 06/01/2005 - "Linkage study of the glucagon receptor gene with type 2 diabetes mellitus in Italians." 07/01/1996 - "Recent studies have shown both association and linkage between a Gly40-Ser mutation in the glucagon receptor gene and NIDDM in French patients with familial NIDDM. " 11/01/2014 - "A potent novel compound (MK-3577) was developed for the treatment of type 2 diabetes mellitus (T2DM) through blocking the glucagon receptor. "
3.	Insulin Resistance 05/01/2008 - "This supports the idea that glucagon receptor blockade may be beneficial in treating insulin resistance and Type 2 diabetic renal complications." 10/01/2013 - "The purpose of this article is to briefly review recently published animal and human studies in this field, and provide new insights and perspectives on recent debates as to whether hyperglucagonemia and/or glucagon receptors should be targeted to treat insulin resistance and target organ injury in type 2 diabetes." 07/01/2007 - "Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet."
4.	Obesity 02/01/2015 - "Strategies enabling either inhibition or activation of glucagon receptor (Gcgr) signaling are being explored for the treatment of diabetes or obesity. " 12/01/2014 - "These data indicate that peptide-based glucagon receptor antagonists can reverse aspects of genetically and dietary-induced obesity-related diabetes." 12/01/2014 - "To examine the effect of two novel, enzymatically stable, glucagon receptor peptide antagonists, on metabolic control in two mouse models of obesity/diabetes. " 06/01/2014 - "Moreover, glucagon receptor agonism has also been used as a therapeutic strategy to treat obesity. " 09/01/2012 - "Targeting the glucagon receptor family for diabetes and obesity therapy."
5.	Hypertension (High Blood Pressure) 10/01/2001 - "A higher prevalence of hypertension has been associated with the G-->A/GT (Gly40Ser) polymorphism of the glucagon receptor gene (GCGR) in two population studies. " 07/01/1999 - "Glucagon receptor gene mutation (Gly40Ser) in human essential hypertension: the PEGASE study." 03/01/1999 - "Our results demonstrate a strong genetic heterogeneity among the ethnic group and suggest that the Gly40Ser mutation of the glucagon receptor gene plays little role, if any, in the pathogenesis of type 2 diabetes and essential hypertension in the Taiwanese population." 03/01/1999 - "Screening for the Gly40Ser mutation in the glucagon receptor gene among patients with type 2 diabetes or essential hypertension in Taiwan." 12/01/1996 - "Gly40Ser mutation of glucagon receptor gene and essential hypertension in Japanese."

Related Drugs and Biologics

1.	Glucagon (Glukagon)
2.	Insulin (Novolin)
3.	Glucose (Dextrose)
4.	glucagon-like peptide receptor (receptor, glucagon-like peptide)
5.	Proglucagon (Glucagon Precursors)
6.	Cyclic AMP (AMP, Cyclic)
7.	fibroblast growth factor 21
8.	sulfonylurea receptor
9.	Glucagon-Like Peptide 1 (GLP 1)
10.	Oxyntomodulin

Related Therapies and Procedures

1.	Anesthesia